Advertisement

Menopause and aging: Changes in the immune system—A review

  • Cátia Morgado Gameiro
    Affiliations
    Department of Gynaecology and Obstetrics, Garcia de Orta's Hospital, Almada, Portugal
    Search for articles by this author
  • Fatima Romão
    Affiliations
    Department of Gynaecology and Obstetrics, Garcia de Orta's Hospital, Almada, Portugal
    Search for articles by this author
  • Camil Castelo-Branco
    Correspondence
    Corresponding author at: Institut Clínic de Ginecologia, Obstetrícia i Neonatología, University of Barcelona, Hospital Clínic, Villarroel 170, 08036 Barcelona, Spain. Tel.: +34 93 227 54 36; fax: +34 93 227 93 25.
    Affiliations
    Clinic Institute of Gynecology, Obstetrics and Neonatology, Faculty of Medicine-University of Barcelona, Hospital Clinic-Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
    Search for articles by this author

      Abstract

      Background

      The higher risk of women developing autoimmune diseases suggests that immune system is mediated by sex steroids.

      Objective

      To review the effects of aging and menopause in immune system.

      Methods

      A systematic review of in vitro, animal and human studies involving aging and menopause and immune system was carried out. An electronic search based on Internet search engines, MEDLINE (1966–June 2010) and the Cochrane Controlled Clinical Trials Register was done.

      Results

      After crossing-cleaning the reference lists, a total of 688 studies dealing with immune system and menopause were identified. Of them, 30 were considered selectable. The concept of immunosenescence reflects changes in both cellular and serological immune responses throughout the process of generating specific response to foreign antigens. This may be related with a higher incidence of infectious and chronic diseases. After menopause, there is an increase in pro-inflammatory serum markers (IL1, IL6, TNF-alpha), an increase in response of the immune blood cells to these cytokines, a decrease in CD4 T and B lymphocytes and a decrease in the cytotoxic activity of NK cells. Additionally, IL-6 is a key factor in bone resorption and also seems to be associated with other diseases more common after menopause such as diabetes, atherosclerosis and cardiovascular disease.

      Conclusions

      Most of the studies suggested that in addition to age, in postmenopausal women, changes of the immune system have been attributed to estrogen deprivation. Furthermore, recent studies point out changes in immune response related to use or cessation of hormone replacement at menopause.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Maturitas
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Dennerstein L.
        Well-being, symptoms and the menopausal transition.
        Maturitas. 1996; 23: 147-157
        • Dennerstein L.
        • Dudley E.C.
        • Hopper J.L.
        • Guthrie J.R.
        • Burgr H.G.
        A prospective population-based study of menopausal symptoms.
        Obstet Gynecol Obstet. 2000; 96: 351-358
        • Grossman C.J.
        • Roselle G.A.
        • Mendenhall C.L.
        Sex steroid regulation of autoimmunity.
        J Steroid Biochem Mol Biol. 1991; 40: 649-659
        • Weiskopf D.
        • Weinbereger B.
        • Grubeck-Loebenstein B.
        Theaging of the immune system.
        Transpl Int. 2009; 22: 1041-1050
        • Krabbe K.S.
        • Pedersen M.
        • Brunsgaard H.
        Inflammatory mediators in the elderly.
        Exp Gerontol. 2004; 39: 687-699
        • Olsen N.J.
        • Kovacs W.J.
        Gonadal steroids and immunity.
        Endocr Rev. 1996; 17: 369-384
        • Medeiros S.F.
        • Oliveira V.N.
        • Yamamoto M.M.W.
        Epidemiologia clínica do climatério.
        Reprod Clim. 2003; 18: 79-86
        • Basedovsky H.O.
        • Del Rey A.
        Immune–neuro–endocrine interactions: facts and hypotheses.
        Endocr Rev. 1996; 17: 64-102
        • Medeiros S.F.
        • Alexandre M.
        • Nince A.P.B.
        Efeitos da terapia hormonal na menopausa sobre o sistema imune.
        Rev Brás Ginecol Obestet. 2007; 29: 593-601
        • Goldsby A.R.
        • Kindt J.T.
        • Osborne A.B.
        Kuby immunology. Fourth ed. 2000: 508-509 (Chapter 20)
        • Ho H.N.
        • Wu M.Y.
        • Chen H.F.
        • et al.
        In vivo CD3+CD25+ lymphocyte subpopulation is down-regulated without increased serum-soluble interleukin-2 receptor (sIL-2R) by gonadotropin releasing hormone agonist (GnRH-a).
        Am J Reprod Immunol. 1995; 33: 134-139
        • Cutolo M.
        • Capellino S.
        • Sulli A.
        • et al.
        Estrogens and autoimmune diseases.
        Ann N Y Acad Sci. 2006; 1089: 538-547
        • Faas M.
        • Bouman A.
        • Moes H.
        • Heineman M.J.
        • de Leij L.
        • Schuiling G.
        The immune response during the luteal phase of the ovarian cycle: a Th2-type response?.
        Fertil Steril. 2000; 74: 1008-1013
        • Shakhar K.
        • Shakhar G.
        • Rosenne E.
        • Ben-Eliyahu S.
        Timing within the menstrual cycle, sex, and the use of oral contraceptives determine adrenergic suppression of NK cell activity.
        Br J Cancer. 2000; 83: 1630-1636
        • White H.D.
        • Crassi K.M.
        • Givan A.L.
        • et al.
        CD3+CD8+CTL activity within the human female reproductive tract: influence of stage of menstrual cycle and menopause.
        J Immunol. 1997; 158: 3017-3027
        • Tonet A.C.
        • Nóbrega O.T.
        Immunosenescence: the association between leukocytes, cytokines and chronic diseases.
        Rev Bras Geriatr Gerontol. 2008; 11: 259-273
        • Weiskopf D.
        • Weinberger B.
        • Grubeck-Loebenstein B.
        The aging of the immune system.
        Transpl Int. 2009; 22 (Epub 2009 July 16): 1041-1050
        • Grolleau- Julius A.
        • Ray D.
        • Yung R.L.
        The role of epigenetics in agin and autoimmunity.
        Clin Rev Allergy Immunol. 2010; 39: 42-50
        • Khansari N.
        • Shakiba Y.
        • Mahmoidi M.
        Chronic inflammation and oxidative stress as a major cause of age-related disease and cancer.
        Recent Pat Inflamm Allergy Drug Discov. 2009; 3: 73-80
        • Giglio T.
        • Imro M.A.
        • Filaci G.
        • et al.
        Immune cell circulating subsets are affected by gonadal function.
        Life Sci. 1994; 54: 1305-1312
        • Kamada M.
        • Irahara M.
        • Maegawa M.
        • et al.
        Postmenopausal changes in serum cytokine levels and hormone replacement therapy.
        Am J Obstet Gynecol. 2001; 184: 309-314
        • Yasui T.
        • Maegawa M.
        • Tomita J.
        • et al.
        Changes in serum cytokine concentrations during the menopausal transition.
        Maturitas. 2007; 56: 396-403
        • Cioffi M.
        • Esposito K.
        • Vietri M.T.
        • et al.
        Cytocine patern in postmenopauce.
        Maturitas. 2002; 41: 187-192
        • Coulam C.B.
        • Stern J.J.
        Immunology of ovarian failure.
        Am J Reprod Immunol. 1991; 25: 169-174
        • Pfeilschifter J.
        • Koditz R.
        • Pfohl M.
        • Schatz H.
        Changes in proinflammatory cytokine activity after menopause.
        Endocr Rev. 2002; 23: 90-119
        • Toshiyuki Y.
        • Hirokazu U.
        • Masayo Y.
        • et al.
        Associations of interleukin-6 with interleukin 1Beta, interleukin-8 and macrophage inflammatory protein 1Beta in midlife women.
        Cytokine. 2008; 41: 302-306
        • William B.
        • Ershler S.
        • Harman M.
        • Even T.
        Immunologic aspects of osteoporosis.
        Dev Comp Immunol. 1997; 21: 487-499
        • Pacifici R.
        Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis.
        J Bone Miner Res. 1996; 11: 1043-1051
        • Straub R.H.
        • Hense H.W.
        • Andus T.
        • Scholmerich J.
        • Riegger G.A.
        • Schunkert H.
        Hormone replacement therapy and interrelation between serum interleukin-6 and body mass index in postmenopausal women: a population-based study.
        J Clin Endocrinol Metab. 2000; 85: 1340-1344
        • Brooks-Asplund E.M.
        • Tupper C.E.
        • Daun J.M.
        • Kenney W.L.
        • Cannon J.G.
        Hormonal modulation of interleukin-6, tumor necrosis factor and associated receptor secretion in postmenopausal women.
        Cytokine. 2002; 19: 193-200
        • Blum M.
        • Zacharovich D.
        • Pery J.
        • KitAi E.
        Lowering effect of estrogen replacement treatment on immunoglobolins in menopausal women.
        Rev Fr Gynecol Obstet. 1990; 85: 207-209
        • Stopinska-Gluszack U.
        • Waligóra J.
        • Grazela T.
        • et al.
        Effect of estrogen/progesterone hormone replacement therapy on natural killer cell cytotoxicity and immunoregulatory cytokine release by peripheral blood mononuclear cells of postmenopausal womem.
        J Reprod Immunol. 2006; 69: 65-75
        • Ryan-Borchers T.A.
        • Park J.S.
        • Chew B.P.
        • McGuire M.K.
        • Fournier L.R.
        • Beerman K.A.
        Soy isoflavones modulate immune function in helthy postmenopausal women.
        Am J Clin Nutr. 2006; 83: 1118-1125
        • Koh K.K.
        • Schenke W.H.
        • Waclawiw M.
        • Csako G.
        • Cannon III, R.O.
        Statin attenuates increase in C-reactive protein during estrogen replacement therapy in postmenopausal women.
        Circulation. 2002; 105: 1531-1533
        • Cushman M.
        • Legault C.
        • Barrett-Connor E.
        • et al.
        Effect of postmenopausal hormones on inflammation-sensitive proteins. The postmenopausal estrogen/progestin interventions (PEPI) study.
        Circulation. 1999; 100: 717-722
        • Vehkavaara S.
        • Silveira A.
        • Hakala-Ala-Pietila T.
        • et al.
        Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women.
        Thromb Haemost. 2001; 85: 619-625
        • Herrington D.M.
        • Brosnihan K.B.
        • Pusser B.E.
        • et al.
        Differential effects of estrogen and droloxifene on C-reactive protein and other markers of inflammation in healthy postmenopausal women.
        J Clin Endocrinol Metab. 2001; 86: 4216-4222
        • Cushman M.
        • Meilahn E.N.
        • Psaty B.M.
        • Kuller L.H.
        • Dobs A.S.
        • Tracy R.P.
        Hormone replacement therapy, inflammation, and hemostasis in elderly women.
        Arterioscler Thromb Vasc Biol. 1999; 19: 893-899
        • Walsh B.W.
        • Cox D.A.
        • Sashegyi A.
        • Dean R.A.
        • Tracy R.P.
        • Anderson P.W.
        Role of tumor necrosis factor-α and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women.
        Am J Cardiol. 2001; 88: 825-828
        • Silvestri A.
        • Gebara O.
        • Vitale C.
        • et al.
        Increased levels of C-reactive protein after oral hormone replacement therapy may not be related to an increased inflammatory response.
        Circulation. 2003; 107: 3165-3169
        • Decensi A.
        • Omodei U.
        • Robertson C.
        • et al.
        Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women.
        Circulation. 2002; 106: 1224-1228
        • Sattar N.
        • Perera M.
        • Small M.
        • Lumsden M.A.
        Hormone replacement therapy and sensitive C-reactive protein concentrations in women with type-2 diabetes.
        Lancet. 1999; 354: 487-488
        • Modena M.G.
        • Bursi F.
        • Fantini G.
        • et al.
        Low-grade inflammation and estimates of insulin resistance during the menstrual cycle in lean and overweight women.
        J Clin Endocrinol Metab. 2005; 90: 3230-3235
        • Caulin-Glaser T.
        • Watson C.A.
        • Pardi R.
        • Bender J.R.
        Effects of 17β-estradiol on cytokine-induced endothelial cell adhesion molecule expression.
        J Clin Invest. 1996; 98: 36-42
        • Miller A.P.
        • Feng W.
        • Xing D.
        • et al.
        Estrogen modulates inflammatory mediator expression and neutrophil chemotaxis in injured arteries.
        Circulation. 2004; 110: 1664-1669
        • Wakatsuki A.
        • Okatani Y.
        • Ikenoue N.
        • Fukaya T.
        Effect of medroxyprogesterone acetate on vascular inflammatory markers in postmenopausal women receiving estrogen.
        Circulation. 2002; 105: 1436-1439
        • Lamon-Fava S.
        • Posfai B.
        • Schaefer E.J.
        Effect of hormonal replacement therapy on C-reactive protein and cell-adhesion molecules in postmenopausal women.
        Am J Cardiol. 2003; 91: 252-254
        • Koh K.K.
        • Bui M.N.
        • Mincemoyer R.
        • Cannon III, R.O.
        Effects of hormone therapy on inflammatory cell adhesion molecules in postmenopausal healthy women.
        Am J Cardiol. 1997; 80: 1505-1507
        • Koh K.K.
        • Blum A.
        • Hathaway L.
        • et al.
        Vascular effects of estrogen and vitamin E therapies in postmenopausal women.
        Circulation. 1999; 100: 1851-1857
        • Koh K.K.
        • Jin D.K.
        • Yang S.H.
        • et al.
        Vascular effects of synthetic or natural progestagen combined with conjugated equine estrogen in healthy postmenopausal women.
        Circulation. 2001; 103: 1961-1966
        • Pervin S.
        • Singh R.
        • Rosenfeld M.E.
        • Navab M.
        • Chaudhuri G.
        • Nathan L.
        Estradiol suppresses MCP-1 expression in vivo: implications for atherosclerosis.
        Arterioscler Thromb Vasc Biol. 1998; 18: 1575-1582
        • Stork S.
        • Baumann K.
        • von Schacky C.
        • Angerer P.
        The effect of 17 beta-estradiol on MCP-1 serum levels in postmenopausal women.
        Cardiovasc Res. 2002; 53: 642-649
        • Koh K.K.
        • Son J.W.
        • Jin D.K.
        • et al.
        Effect of hormone replacement therapy on nitric oxide bioactivity and monocyte chemoattractant protein-1 levels.
        Int J Cardiol. 2001; 81: 43-50
        • Srivastava S.
        • Weitzmann M.N.
        • Cenci S.
        • Ross F.P.
        • Adler S.
        • Pacifici R.
        Estrogen decreases TNF gene expression by blocking JNK activity and the resulting production of c-Jun and JunD.
        J Clin Invest. 1999; 104: 503-513
        • Koh K.K.
        • Ahn J.Y.
        • Jin D.K.
        • et al.
        Effects of continuous combined hormone replacement therapy on inflammation in hypertensive and/or overweight postmenopausal women.
        Arterioscler Thromb Vasc Biol. 2002; 22: 1459-1464
        • Sukovich D.A.
        • Kauser K.
        • Shirley F.D.
        • DelVecchio V.
        • Halks-Miller M.
        • Rubanyi G.M.
        Expression of interleukin-6 in atherosclerotic lesions of male apoE-knockout mice.
        Arterioscler Thromb Vasc Biol. 1998; 18: 1498-1505